Servicio de Información Comunitario sobre Investigación y Desarrollo - CORDIS

CORDIS reúne toda la información sobre los proyectos financiados por Horizonte 2020 , y ahora también resúmenes de los informes relacionados. Se puede descargar toda la documentación de estos proyectos en el Portal de datos abiertos de la UE .

My refinements

Download results of this page

Restringir por:

Tipo de contenido

Proyecto (40)

Advanced search

Búsqueda de proyectos y resultados

Results 1 - 10 of 40
12 3 4 > 
ID: 731875
Fecha de inicio: 2017-01-01, Fecha de finalización: 2021-12-31
Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic...
Programme: H2020-EU.3.1.3.
Record Number: 207204
Last updated on: 2017-06-02
Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer
ID: 733008
Fecha de inicio: 2017-01-01, Fecha de finalización: 2022-12-31
IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a...
Programme: H2020-EU.3.1.3.
Record Number: 207443
Last updated on: 2017-07-17
Multisystem Cell Therapy for Improvement of Urinary Continence
ID: 731377
Fecha de inicio: 2017-01-01, Fecha de finalización: 2021-12-31
"Stress Urinary Incontinence (SUI) is a disease affecting over 200 million people worldwide. It represents a condition with a prevalence of 20-50% in women, thereby creating an immense socio-economic burden. The currently available treatment strategies entail various...
Programme: H2020-EU.3.1.3.
Record Number: 207193
Last updated on: 2017-07-14
Drug CandIdates ScreenINg
[PROYECTO] DeCISIoN - Drug CandIdates ScreenINg
ID: 726513
Fecha de inicio: 2016-07-01, Fecha de finalización: 2018-12-31
Pluriomics is an international Dutch/Belgian biotech company specialised in developing stem cell-based assays for cardiac safety pharmacology and drug discovery and development. Pluriomics developed a unique proprietary protocol to differentiate heart muscle cells derived from...
Programme: H2020-EU.3.1.3.
Record Number: 204232
Last updated on: 2017-06-23
Clinical trial of autologous adipose-derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis
ID: 643809
Fecha de inicio: 2015-01-01, Fecha de finalización: 2018-12-31
Osteoarthritis (OA) is an incurable disease...
Programme: H2020-EU.3.1.3.
Record Number: 194107
Last updated on: 2017-08-22
Pancreatic cancer as a treatment target of Dwarfbody-Therapeutics
ID: 763138
Fecha de inicio: 2017-03-01, Fecha de finalización: 2017-08-31
Dwarfbody-Therapeutics (DB-Tx) is a new company, established in 2016 as a spin off from a frontrunner research team in Gastro-Intestinal Cancers in the AMC Amsterdam. DB-Tx aims to transform current, ineffective treatment of these aggressive cancer types by co-administering...
Programme: H2020-EU.3.1.3.
Record Number: 208178
Last updated on: 2017-02-07
Scale-up of Prevention and Management of Alcohol Use Disorders and Comorbid Depression in Latin America
ID: 778048
Fecha de inicio: 2017-12-01, Fecha de finalización: 2021-11-30
Following the strategic approach of the Global Alliance for Chronic Diseases (GACD) to support optimal approaches to implement existing knowledge, SCALA implements and evaluates an evidence-based approach to scale up prevention and management of Alcohol Use Disorders (AUD) and...
Programme: H2020-EU.3.1.3.
Record Number: 213001
Last updated on: 2018-01-24
Randomized, Comparison Of Risk-Stratified versus Standard Breast Cancer Screening In European Women Aged 40-74
ID: 755394
Fecha de inicio: 2018-01-01, Fecha de finalización: 2025-12-31
MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe. Indeed current standard mammographic screening, with entry stratified by age alone, has recently been largely questioned. Despite a demonstrated mean 20% reduction in breast...
Programme: H2020-EU.3.1.3.
Record Number: 212694
Last updated on: 2018-01-23
Stem-cell based gene therapy for recombination deficient SCID (RECOMB)
ID: 755170
Fecha de inicio: 2018-01-01, Fecha de finalización: 2022-12-31
Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SCID) have been successfully treated by autologous stem cell based gene therapy. However, for the most common group of SCID, the SCID...
Programme: H2020-EU.3.1.3.
Record Number: 212687
Last updated on: 2018-01-23
Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome
ID: 755225
Fecha de inicio: 2018-01-01, Fecha de finalización: 2022-12-31
Crigler-Najjar syndrome (CN) is a rare recessive disorder caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1(UGT1A1) gene. CN is a life-threatening disease with no cure which constitutes a severe burden for the patients, their families, and the society...
Programme: H2020-EU.3.1.3.
Record Number: 212689
Last updated on: 2018-01-23
12 3 4 > 
List retrieved on: 2018-06-18
Síganos en: RSS Facebook Twitter YouTube Gestionado por la Oficina de Publicaciones de la UE Arriba